Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dermata Therapeutics Inc (DRMA)

Dermata Therapeutics Inc (DRMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,039
  • Shares Outstanding, K 1,510
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,790 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 0.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.92
  • Growth Rate Est. (year over year) +52,131.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +4.10%
on 10/14/24
1.6800 -24.40%
on 10/18/24
-0.3700 (-22.56%)
since 09/30/24
3-Month
1.2200 +4.10%
on 10/14/24
3.7900 -66.49%
on 08/02/24
-0.5000 (-28.25%)
since 07/30/24
52-Week
1.2200 +4.10%
on 10/14/24
14.6250 -91.32%
on 11/16/23
-7.4300 (-85.40%)
since 10/30/23

Most Recent Stories

More News
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea

- Topline results expected in the second half of 2022 -

DRMA : 1.2700 (-5.93%)
Dermata to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic...

DRMA : 1.2700 (-5.93%)
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA;...

DRMA : 1.2700 (-5.93%)
DRMAW : 0.0124 (+49.40%)
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of...

DRMA : 1.2700 (-5.93%)
DRMAW : 0.0124 (+49.40%)
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment...

DRMA : 1.2700 (-5.93%)
DRMAW : 0.0124 (+49.40%)
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results

DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase...

DRMA : 1.2700 (-5.93%)
DRMAW : 0.0124 (+49.40%)
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic...

DRMA : 1.2700 (-5.93%)
Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic...

DRMA : 1.2700 (-5.93%)
Dermata to Present at the H.C. Wainwright BioConnect Conference

SAN DIEGO, CA / ACCESSWIRE / January 5, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic...

DRMA : 1.2700 (-5.93%)
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions

- Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance - Duration of effect lasted approximately 3 months - No potential distant spread of toxin observed SAN DIEGO,...

DRMA : 1.2700 (-5.93%)

Business Summary

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions.

See More

Key Turning Points

3rd Resistance Point 1.4800
2nd Resistance Point 1.4300
1st Resistance Point 1.3500
Last Price 1.2700
1st Support Level 1.2200
2nd Support Level 1.1700
3rd Support Level 1.0900

See More

52-Week High 14.6250
Fibonacci 61.8% 9.5043
Fibonacci 50% 7.9225
Fibonacci 38.2% 6.3407
Last Price 1.2700
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar